The Korea Pharmaceutical and Bio-Pharma Association announced on the 7th that it would begin the 'Digital History Museum and Archive Construction Project' to systematically organize the nearly 130-year history of the pharmaceutical and bio industry and communicate with the public online. This is one of the commemorative projects for the association's 80th anniversary. The association has also started preparations for a domestic new drug storybook, a pharmaceutical advertising white paper, a history of 80 years, and a construction project for a pharmaceutical and bio industry exhibition hall. The digital history museum, which will compile the 129 years of industrial growth since the founding of the first pharmaceutical company, Dongwha Pharm, in 1897, will consist of industry and association halls and archives. It will be built to allow an examination of the flow of major turning points by classifying the significant history of the industry and the association by theme. The archive will contain various materials that allow for a look at the history of the industry, including literature of historical value, photographs, videos, and advertising and campaign materials. The 80-year history will be produced in e-book format and posted in the digital history museum, with limited print copies for distribution.
Celltrion announced on the 7th that it disclosed the global phase 3 long-term post-analysis results of the subcutaneous injection autoimmune disease treatment, 'CT-P13 SC' (U.S. brand name Jimpentra) at the '2025 Crohn's Disease and Colitis Congress' (CCC). This is related to the results of increased dosage during the 102-week (approximately 2 years) long-term follow-up study of the global clinical phase 3 of Jimpentra. The phase 3 clinical trial was conducted on 192 patients with Crohn's disease and 237 patients with ulcerative colitis. Patients for whom increased treatment was deemed necessary after 22 weeks showed significant improvements in clinical remission and clinical and endoscopic responses when evaluating the degree of symptom improvement at the 102-week mark. Most patients who received an increased dosage showed better efficacy within 8 weeks after the increase. Safety did not show significant differences compared to the non-increased dosage group, and no new safety concerns were identified.
Dongkook Pharmaceutical announced on the 7th that it has launched three types of 'Beautiful Ling Oil Gargle.' The products are oil pulling (gargling with oil in the mouth) items made with a golden ratio of 8:92, containing 'golden jojoba oil' and 'Ayurvedic blended herbs' extracted through unrefined cold-pressing processes. According to the company, it has been proven to reduce 12 types of oral bacteria that cause oral toxins and three types of bad breath gases that are the main culprits of halitosis. Unlike the traditional oil pulling method, which requires holding in the mouth for over 10 minutes, users can feel freshness and smoothness in their mouth in just about 30 seconds.
Noul announced on the 7th that it has obtained fundamental patents for its core technology, contact-type patches and dyeing methods using them, from the U.S. Patent and Trademark Office (USPTO). The patent obtained by Noul relates to a dyeing method using contact dyeing patches that store dyeing samples and solvents together inside a gel structure. The company explained that this technology allows for a cartridge configuration that does not require liquid, enabling the acquisition of diagnostic test results quickly and conveniently. The overall dyeing process is simplified, and there is a significant reduction in the amount of dyeing samples required for diagnosis.
The Jaseng Medical Foundation's Spine and Joint Research Institute held the '1st PIM Paper Competition' award ceremony on the 6th at the Jaseng Medi-Bio Center in Seongnam, Gyeonggi Province. PIM (Perspectives on Integrative Medicine) is an international academic journal specializing in integrative medicine that the Jaseng Medical Foundation's Spine and Joint Research Institute launched in October 2022, and it is composed of over 50 editorial members including officials from Harvard University, Columbia University, and the University of Tokyo. Jeong Hye-in, a Korean medicine doctor from Kyunghee University, received the grand prize for her paper on the effects of acupuncture treatment on relief of labor pain and shortening of labor time in pregnant women. The excellence award was given to Park Geon-woo, an undergraduate student at the College of Korean Medicine at Semyung University, and Kim Seong-jin, a doctoral student at the College of Korean Medicine at Gachon University. Park's research established the evidentiary basis for traditional Korean medicine treatment based on a literature review of acupuncture and herbal medicine for cancer treatment. Kim identified the anti-inflammatory effects of Huanglian detoxifying soup and presented its potential as a treatment method for inflammatory diseases.